NCT00687505已完成1 期
A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 2
- 主要终点
- Safety and tolerability
研究概览
简要总结
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
- •Male or female 18 years of age or older
排除标准
- •Presence or history of melanoma
- •Primary brain tumor
- •Presence or history of glaucoma
研究组 & 干预措施
1
Experimental
Single ascending doses
干预措施: FP-1039 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerRenal Cell CarcinomaColorectal CancerMelanomaBladder CancerNCT06580938Pfizer4
进行中（未招募）
1 期
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell LungNCT06447662Pfizer64
终止
1 期
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseMyelofibrosisNCT02436135Gilead Sciences10
已完成
1 期
A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy VolunteersHealthyNCT01215084Biogen36
进行中（未招募）
1 期
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsOvarian CancerGastric CancerNCT06714617SystImmune Inc.120